NCT01576263

Brief Summary

Total knee and hip arthroplasty for osteoarthritis is performed on still broader indications even in elderly patients with previous or current medical conditions. Especially comorbidity like cardiovascular diseases and conditions with increased risk of bleeding or previous thrombo-embolic events are major challenges. To facilitate safe use of ropivacaine as an analgesic, information on the concentrations levels after autologous blood transfusion following local infiltration analgesia is very crucial. However, very limited data are available. To verify the safety of autologous blood transfusion, ropivacaine concentrations were studied in 52 patients undergoing either total knee arthroplasty or total hip arthroplasty.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2010

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2010

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

April 3, 2012

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 12, 2012

Completed
Last Updated

April 10, 2015

Status Verified

April 1, 2015

Enrollment Period

1 month

First QC Date

April 3, 2012

Last Update Submit

April 9, 2015

Conditions

Keywords

AnaesthesiaInfiltrationBlood transfusionAutologousArthroplastyReplacementRopivacaine

Outcome Measures

Primary Outcomes (1)

  • Concentrations of ropivacaine in serum

    Concentrations of ropivacaine in serum before and after autologous blood transfusion will be analyzed.

    6 hours

Secondary Outcomes (1)

  • Analysis of ECG and pulse rate

    6 hours

Study Arms (2)

Total knee arthroplasty

25 consecutive patients diagnosed for total knee arthroplasty.

Drug: Autologous blood transfusion with ropivacaine

Total hip arthroplasty

27 patients diagnosed for total hip arthroplasty.

Drug: Autologous blood transfusion with ropivacaine

Interventions

Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg

Also known as: No other names.
Total knee arthroplasty

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Primary care clinic.

You may qualify if:

  • Clinical diagnosis for hip arthroplasty
  • Clinical diagnosis for knee arthroplasty

You may not qualify if:

  • Patients \< 18 years
  • Lack of informed consent
  • Inability to read/understand Danish
  • Bilateral diagnosis
  • Cancer diagnosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vendsyssel Hospital, Frederikshavn, Aalborg Hospital, Aarhus University

Aalborg, Denmark

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Venous blood to collect an analysis of total ropivacaine concentrations.

MeSH Terms

Interventions

Blood Transfusion, AutologousRopivacaine

Intervention Hierarchy (Ancestors)

Blood TransfusionBiological TherapyTherapeuticsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Ole Simonsen, M.D.

    Northern Orthopaedic Department, Aalborg University Hospital, Denmark

    PRINCIPAL INVESTIGATOR
  • Sten Rasmussen, M.D.

    Northern Orthopaedic Division, Aalborg University Hospital, Denmark

    STUDY CHAIR
  • Bjarne B. Dencker, M.D.

    Department of Anaesthesiology, Aalborg University Hospital, Denmark

    STUDY CHAIR
  • Torben Breindahl, M.D.

    Department of Clinical Biochemistry, Vendsyssel Hospital, Aarhus University, Denmark

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 3, 2012

First Posted

April 12, 2012

Study Start

March 1, 2010

Primary Completion

April 1, 2010

Study Completion

June 1, 2010

Last Updated

April 10, 2015

Record last verified: 2015-04

Locations